FDA approves second antiviral COVID pill
Merck’s drug, molnupiravir, was found to reduce hospitalizations and deaths by 30 percent, while Pfizer's antiviral pill had a nearly 90 percent reduction.
Opinion
Follow this topic to stay updated on recent posts.
See recent posts